Reuters logo
BRIEF-Selecta Biosciences obtains license for recombinant immunotoxin lmb-100 from National Cancer Institute
May 2, 2017 / 12:16 PM / 5 months ago

BRIEF-Selecta Biosciences obtains license for recombinant immunotoxin lmb-100 from National Cancer Institute

May 2 (Reuters) - Selecta Biosciences Inc

* Selecta biosciences obtains license for recombinant immunotoxin lmb-100 from national cancer institute (nci) for pancreatic cancer, mesothelioma and other cancers

* Selecta biosciences inc - under terms of license agreement, nci will receive an upfront payment of $50,000 from selecta

* Selecta biosciences-nci entitled upto $9.25 million for milestones, low single-digit royalties on worldwide annual sales of any resulting commercialized treatment Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below